2016
DOI: 10.1016/j.bbmt.2016.03.004
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Clinical efficacy of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis has been demonstrated in haploidentical and HLA-matched bone marrow but not in unrelated peripheral blood stem cell (PBSC) transplantations. Also, no direct comparisons have been published with current standard of care, combination of antithymocyte globulin (ATG), calcineurin inhibitors, and either methotrexate or mycophenolate mofetil (MMF). Eighty-six adult patients (median age 34 years; range, 1… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

9
62
1

Year Published

2016
2016
2023
2023

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 98 publications
(72 citation statements)
references
References 40 publications
9
62
1
Order By: Relevance
“…These rates compare favorably with historical rates reported in the literature using conventional GVHD prophylaxis or to a reported comparator group including ATG. 31 Finally, in a retrospective comparative study of haplo and UD transplant recipients, all of whom were treated with PTCY, CNI, and MMF, Rashidi et al 32 reported no significant difference in the incidence of acute or chronic GVHD (there were no significant differences found in any outcome, with the exception of neutrophil engraftment, which was faster after UD transplantation).…”
Section: 27mentioning
confidence: 99%
See 1 more Smart Citation
“…These rates compare favorably with historical rates reported in the literature using conventional GVHD prophylaxis or to a reported comparator group including ATG. 31 Finally, in a retrospective comparative study of haplo and UD transplant recipients, all of whom were treated with PTCY, CNI, and MMF, Rashidi et al 32 reported no significant difference in the incidence of acute or chronic GVHD (there were no significant differences found in any outcome, with the exception of neutrophil engraftment, which was faster after UD transplantation).…”
Section: 27mentioning
confidence: 99%
“…30,31 In these 4 studies, the incidence of grade III-IV GVHD is between 0% and 19% (.8% in 1 study only), and the incidence of chronic GVHD is between 11% and 22%. These rates compare favorably with historical rates reported in the literature using conventional GVHD prophylaxis or to a reported comparator group including ATG.…”
Section: 27mentioning
confidence: 99%
“…The mean purpose of this therapy is to abrogate effects of activated alloreactive T lymphocytes, thus allowing to decrease acute GVHD risk by 30%. However, most published data describes treatment of adult patients with hematological malignancies [5,6], several studies in pediatric HSCT are also based on this category of patients. Hence, the aim of the present study was to assess efficiency of PTCy therapy in pediatric patients with non-malignant diseases.…”
Section: Introductionmentioning
confidence: 99%
“…The integration of PTCy into MUD and MRD transplant protocols is ongoing and comparison to haplo-HCT protocols would be illuminating. 92,93 Data comparing GIAC and selective TCD platforms with PTCybased protocols is lacking. These questions need to be answered in the context of prospective clinical trials.…”
Section: Future Directionsmentioning
confidence: 99%